Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Bank of America Co. 

West Pharmaceutical Services Inc. diskutieren

West Pharmaceutical Services Inc.

WKN: 864330 / Symbol: WST / Name: West Pharmaceutical Services / Aktie / Ausrüstung & Versorgung / Mid Cap /

262,50 €
4,23 %

Einschätzung Buy
Rendite (%) -6,69 %
Kursziel 369,72
Veränderung
Endet am 16.06.24

West Pharmaceutical Services, Inc. (NYSE: WST) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $405.00 price target on the stock, up previously from $390.00.
Ratings data for WST provided by MarketBeat

Einschätzung Buy
Rendite (%) -20,72 %
Kursziel 349,62
Veränderung
Endet am 28.07.24

West Pharmaceutical Services, Inc. (NYSE: WST) had its price target raised by analysts at KeyCorp from $375.00 to $385.00. They now have an "overweight" rating on the stock.
Ratings data for WST provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,38 %
Kursziel 368,24
Veränderung
Endet am 27.10.24

West Pharmaceutical Services, Inc. (NYSE: WST) had its price target lowered by analysts at Stephens from $420.00 to $390.00. They now have an "overweight" rating on the stock.
Ratings data for WST provided by MarketBeat

West Pharmaceutical Services, Inc. (NYSE: WST) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for WST provided by MarketBeat

Einschätzung Buy
Rendite (%) -30,87 %
Kursziel 497,52
Veränderung
Endet am 07.02.25

West Pharmaceutical Services, Inc. (NYSE: WST) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $536.00 price target on the stock, up previously from $323.00.
Ratings data for WST provided by MarketBeat

Einschätzung Buy
Rendite (%) -29,59 %
Kursziel 438,98
Veränderung
Endet am 13.02.25

West Pharmaceutical Services, Inc. (NYSE: WST) had its price target raised by analysts at KeyCorp from $440.00 to $470.00. They now have an "overweight" rating on the stock.
Ratings data for WST provided by MarketBeat